These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36843330)

  • 1. Change in Cerebrospinal Fluid Tau Microtubule Binding Region Detects Symptom Onset, Cognitive Decline, Tangles, and Atrophy in Dominantly Inherited Alzheimer's Disease.
    Horie K; Li Y; Barthélemy NR; Gordon B; Hassenstab J; Benzinger TLS; Fagan AM; Morris JC; Karch CM; Xiong C; Allegri R; Mendez PC; Ikeuchi T; Kasuga K; Noble J; Farlow M; Chhatwal J; Day G; Schofield PR; Masters CL; Levin J; Jucker M; Lee JH; Roh JH; Sato C; Sachdev P; Koyama A; Reyderman L; Bateman RJ; McDade E;
    Ann Neurol; 2023 Jun; 93(6):1158-1172. PubMed ID: 36843330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease.
    Horie K; Barthélemy NR; Sato C; Bateman RJ
    Brain; 2021 Mar; 144(2):515-527. PubMed ID: 33283854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.
    Horie K; Salvadó G; Barthélemy NR; Janelidze S; Li Y; He Y; Saef B; Chen CD; Jiang H; Strandberg O; Pichet Binette A; Palmqvist S; Sato C; Sachdev P; Koyama A; Gordon BA; Benzinger TLS; Holtzman DM; Morris JC; Mattsson-Carlgren N; Stomrud E; Ossenkoppele R; Schindler SE; Hansson O; Bateman RJ
    Nat Med; 2023 Aug; 29(8):1954-1963. PubMed ID: 37443334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
    Gordon BA; Blazey TM; Christensen J; Dincer A; Flores S; Keefe S; Chen C; Su Y; McDade EM; Wang G; Li Y; Hassenstab J; Aschenbrenner A; Hornbeck R; Jack CR; Ances BM; Berman SB; Brosch JR; Galasko D; Gauthier S; Lah JJ; Masellis M; van Dyck CH; Mintun MA; Klein G; Ristic S; Cairns NJ; Marcus DS; Xiong C; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
    Brain; 2019 Apr; 142(4):1063-1076. PubMed ID: 30753379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
    Morenas-Rodríguez E; Li Y; Nuscher B; Franzmeier N; Xiong C; Suárez-Calvet M; Fagan AM; Schultz S; Gordon BA; Benzinger TLS; Hassenstab J; McDade E; Feederle R; Karch CM; Schlepckow K; Morris JC; Kleinberger G; Nellgard B; Vöglein J; Blennow K; Zetterberg H; Ewers M; Jucker M; Levin J; Bateman RJ; Haass C;
    Lancet Neurol; 2022 Apr; 21(4):329-341. PubMed ID: 35305339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease.
    Lim YY; Maruff P; Barthélemy NR; Goate A; Hassenstab J; Sato C; Fagan AM; Benzinger TLS; Xiong C; Cruchaga C; Levin J; Farlow MR; Graff-Radford NR; Laske C; Masters CL; Salloway S; Schofield PR; Morris JC; Bateman RJ; McDade E;
    JAMA Neurol; 2022 Mar; 79(3):261-270. PubMed ID: 35099506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC
    Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.
    Twohig D; Rodriguez-Vieitez E; Sando SB; Berge G; Lauridsen C; Møller I; Grøntvedt GR; Bråthen G; Patra K; Bu G; Benzinger TLS; Karch CM; Fagan A; Morris JC; Bateman RJ; Nordberg A; White LR; Nielsen HM;
    Acta Neuropathol Commun; 2018 Nov; 6(1):130. PubMed ID: 30477568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease.
    Lim YY; Hassenstab J; Goate A; Fagan AM; Benzinger TLS; Cruchaga C; McDade E; Chhatwal J; Levin J; Farlow MR; Graff-Radford NR; Laske C; Masters CL; Salloway S; Schofield P; Morris JC; Maruff P; Bateman RJ;
    Ann Neurol; 2018 Sep; 84(3):424-435. PubMed ID: 30014553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
    Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
    Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological mechanisms of resilience to tau pathology in Alzheimer's disease.
    Svenningsson AL; Bocancea DI; Stomrud E; van Loenhoud A; Barkhof F; Mattsson-Carlgren N; Palmqvist S; Hansson O; Ossenkoppele R
    Alzheimers Res Ther; 2024 Oct; 16(1):221. PubMed ID: 39396028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease.
    Cicognola C; Brinkmalm G; Wahlgren J; Portelius E; Gobom J; Cullen NC; Hansson O; Parnetti L; Constantinescu R; Wildsmith K; Chen HH; Beach TG; Lashley T; Zetterberg H; Blennow K; Höglund K
    Acta Neuropathol; 2019 Feb; 137(2):279-296. PubMed ID: 30547227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimer's disease.
    Lagarde J; Olivieri P; Tonietto M; Tissot C; Rivals I; Gervais P; Caillé F; Moussion M; Bottlaender M; Sarazin M
    J Neurol Neurosurg Psychiatry; 2022 May; 93(5):459-467. PubMed ID: 35228270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease.
    Llibre-Guerra JJ; Li Y; Schindler SE; Gordon BA; Fagan AM; Morris JC; Benzinger TLS; Hassenstab J; Wang G; Allegri R; Berman SB; Chhatwal J; Farlow MR; Holtzman DM; Jucker M; Levin J; Noble JM; Salloway S; Schofield P; Karch C; Fox NC; Xiong C; Bateman RJ; McDade E
    JAMA Netw Open; 2019 Dec; 2(12):e1917126. PubMed ID: 31825500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
    Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
    J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
    Simrén J; Brum WS; Ashton NJ; Benedet AL; Karikari TK; Kvartsberg H; Sjons E; Lussier FZ; Chamoun M; Stevenson J; Hopewell R; Pallen V; Ye K; Pascoal TA; Zetterberg H; Rosa-Neto P; Blennow K
    Alzheimers Res Ther; 2022 Dec; 14(1):192. PubMed ID: 36544221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
    Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
    J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.
    Pettigrew C; Soldan A; Sloane K; Cai Q; Wang J; Wang MC; Moghekar A; Miller MI; Albert M;
    Neuroimage Clin; 2017; 16():439-446. PubMed ID: 28879085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.